期刊
IMMUNOLOGY AND CELL BIOLOGY
卷 84, 期 3, 页码 281-289出版社
WILEY
DOI: 10.1111/j.1440-1711.2006.01441.x
关键词
adoptive immunotherapy; bone marrow transplantation; gene therapy; neoplasm; T lymphocyte
资金
- NCI NIH HHS [P01 CA094237, P01 CA94237] Funding Source: Medline
- NCRR NIH HHS [RR00188] Funding Source: Medline
Adoptive T-cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein-Barr virus-associated post-transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self-antigens and success has been limited in part by inadequate persistence and expansion of transferred T cells and by tumour-evasion strategies. Adoptive immunotherapy presents the opportunity to activate, expand and genetically modify T cells outside the tolerising environment of the host and a number of strategies to optimize the cellular product, including gene modification and modulation of the host environment, in particular by lymphodepletion, have been developed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据